Comprehensive medication guide to Retre-Gel including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
OTC formulations are generally not covered by standard medical insurance; FSA/HSA funds can be used. Prescription formulations administered in a dental office may be billed as part of a dental procedure. Medicare Part D does not typically cover OTC benzocaine.
Estimated Cash Pricing
$5–$15 for OTC equivalents (Orajel Max, Anbesol Max) at retail; $10–$30 for professional dental gel through dental supply channels; as low as $4.35 with a GoodRx coupon for a standard supply.
Medfinder Findability Score
88/100
On this page
Retre-Gel is a brand-name topical anesthetic gel containing 20% benzocaine USP — the maximum available strength for topical use. It is formulated as a flavored, water-soluble gel designed to adhere to oral mucosal tissue and provide rapid surface-level numbing. Retre-Gel is primarily used in dental practice settings and is distributed through dental supply channels rather than retail pharmacy chains.
Benzocaine, the active ingredient in Retre-Gel, belongs to the ester class of local anesthetics. It is one of the most widely used topical anesthetics in the world, found in over 100 brand name products including Orajel, Anbesol, Hurricaine, Dermoplast, and Lanacane. Retre-Gel is specifically the professional dental formulation of this widely available active ingredient.
Retre-Gel is not a controlled substance and does not require any DEA scheduling or special prescribing authorization. The professional dental gel format is labeled "Rx only" in many states, though functionally equivalent consumer products are available over-the-counter without a prescription.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Retre-Gel works through sodium channel blockade. Benzocaine penetrates the lipid-rich nerve cell membrane at the application site and reversibly binds to voltage-gated sodium channels from within. When these channels are blocked, sodium ions cannot rush into the cell, which means the action potential (electrical pain signal) cannot be generated. No signal means no pain sensation — producing local anesthesia without any effect on consciousness.
The onset of numbing with 20% benzocaine gel typically occurs within 30–60 seconds of application to oral mucosa, and the effect lasts approximately 15–30 minutes. Benzocaine's ester chemical structure makes it rapidly effective but with limited tissue penetration — it blocks sensory nerve endings at the surface rather than deeper nerve trunks, making it ideal for pre-injection comfort but not a substitute for injectable anesthesia in deep dental procedures.
Benzocaine is metabolized by plasma cholinesterases upon systemic absorption (typically less than 5% of applied dose) into para-aminobenzoic acid (PABA) and diethylaminoethanol. PABA is then acetylated and excreted in urine. The rapid surface-level onset and limited systemic absorption make benzocaine gel an excellent, well-tolerated choice for most patients needing topical oral anesthesia.
20% — Topical gel
Standard professional dental and consumer OTC formulation; apply small amount to mucosa with applicator up to 4 times daily
10% — Topical gel/cream
Lower-strength formulation available in some consumer products; used for minor skin and mucosal pain relief
5% — Topical gel/ointment
Lower-strength OTC formulation; used for skin surface anesthesia including minor cuts and insect bites
Retre-Gel has a findability score of 88 out of 100 — meaning it is generally available but may require knowing where to look. As of 2026, Retre-Gel is not listed on the FDA's Drug Shortage Database, and benzocaine products as a class remain widely manufactured. However, Retre-Gel specifically is distributed through dental supply channels (Henry Schein, Patterson Dental, Darby Dental) rather than retail pharmacies, which creates a mismatch for patients expecting to find it at CVS or Walgreens.
The 2018 FDA safety communication on methemoglobinemia risk led some manufacturers to discontinue certain benzocaine consumer products, slightly reducing the variety available at retail. However, professional dental gel formulations like Retre-Gel, Hurricaine, and Benzo-Jel were not materially affected. Patients seeking OTC benzocaine gel can reliably find Orajel Maximum Strength or Anbesol Maximum Strength (both 20% benzocaine) at virtually all major retail chains.
If you are struggling to locate Retre-Gel or any benzocaine topical product at your local pharmacy, medfinder can help. Provide your medication, dosage, and ZIP code, and medfinder calls pharmacies near you to check which ones have it in stock. Results are texted directly to you — no hold music, no wasted trips.
Retre-Gel (benzocaine topical) is not a controlled substance and has no DEA scheduling restrictions. Any licensed prescriber may write for it. The professional dental formulation is most commonly prescribed or recommended by dental providers, though physicians and advanced practice providers may also prescribe it.
Dentists (DDS/DMD) — most common prescribers; use it routinely in practice for pre-injection anesthesia
Oral surgeons — use for surgical preparation and post-procedure pain management
Primary care physicians (MD/DO) — can prescribe for oral, mucosal, or skin-surface anesthetic indications
Dermatologists — may prescribe for skin-surface topical anesthetic applications
Nurse practitioners (NPs) and physician assistants (PAs) — full prescribing authority for non-controlled substances in most states
ENT specialists (Otolaryngologists) — may use or prescribe for pharyngeal or mucosal procedures
For most indications, a prescription is not required — OTC benzocaine gel products are available at any major pharmacy or retailer. Telehealth providers can also prescribe benzocaine topical for appropriate indications, though most patients find OTC alternatives sufficient and more conveniently accessible.
No. Retre-Gel (benzocaine topical) is not a controlled substance and is not classified under any DEA schedule. Benzocaine has no known potential for abuse or dependence and does not produce psychoactive effects when used as directed.
The professional dental formulation of Retre-Gel is labeled "Rx only" in many states, meaning a dental or medical prescription may be required to obtain the specific Retre-Gel brand. This is due to its professional-use designation, not any abuse potential or controlled scheduling. Over-the-counter equivalents with 20% benzocaine (Orajel Maximum Strength, Anbesol Maximum Strength) are freely available without a prescription at major retailers.
There are no refill restrictions, quantity limits, or prescription monitoring program (PDMP) requirements associated with benzocaine topical. Any licensed prescriber — including dentists, physicians, nurse practitioners, and physician assistants — can write a prescription for Retre-Gel without any special DEA authorization.
Most patients experience minimal side effects with short-term, low-dose benzocaine use. Common mild reactions include:
Mild stinging or burning sensation at the application site (normal, transient)
Temporary numbness extending slightly beyond the application area
Redness, mild swelling, or irritation at the application site
Skin tenderness, itching, or contact dermatitis (particularly in PABA-sensitive individuals)
Methemoglobinemia (rare but potentially fatal): pale, gray, or blue-colored skin/lips/nails; shortness of breath; confusion; headache; lightheadedness; fast heartbeat; extreme fatigue. Call 911 immediately if these symptoms occur after benzocaine use.
Severe allergic reaction (anaphylaxis): throat swelling, difficulty breathing, drop in blood pressure, hives. Seek emergency care immediately.
Benzocaine is contraindicated in infants and children under 2 years old. High-risk populations include elderly patients, those with G6PD deficiency, hemoglobin-M disease, or NADH-methemoglobin reductase deficiency, and patients with heart disease, asthma, or COPD.
Know what you need? Skip the search.
Lidocaine (topical)
Amide-type local anesthetic; safer pregnancy profile (Category B vs. benzocaine's Category C); available as 2% viscous, 4% solution, or 5% ointment; less risk of methemoglobinemia; preferred alternative for PABA-allergic patients.
EMLA (Lidocaine/Prilocaine)
Eutectic combination of 2.5% lidocaine + 2.5% prilocaine; provides deeper skin anesthesia under occlusion (45-60 min); prescription required; used for IV insertion, skin biopsies, laser procedures. Not for intraoral use.
Tetracaine (topical)
Ester-type local anesthetic like benzocaine; more potent and longer-lasting; available in ophthalmic drops and some dental preparations; not widely available OTC; Rx required.
Dibucaine (Nupercainal)
Amide-type anesthetic available OTC as rectal/hemorrhoidal ointment; longer duration than benzocaine for rectal applications; not an oral substitute.
Prefer Retre-Gel? We can find it.
Nitroglycerin / Nitrates (Imdur, Isordil, Nitrostat)
majorAdditive methemoglobin formation; significantly increases methemoglobinemia risk. Disclose all nitrate medications to dentist before benzocaine use.
Dapsone
majorConcurrent use significantly increases methemoglobinemia risk. Case reports of serious methemoglobinemia in dapsone-treated patients receiving benzocaine during procedures.
Prilocaine / EMLA cream
moderateAdditive methemoglobin formation risk; avoid concurrent use, especially in high-risk patients.
Antimalarials (chloroquine, primaquine)
moderateCan independently cause methemoglobinemia; additive risk with benzocaine.
Sulfonamide antibiotics
moderateMay have additive methemoglobin-forming effects when used concurrently with benzocaine.
Other local anesthetics (injectable lidocaine)
moderateConcurrent use increases total anesthetic load; monitor for signs of anesthetic toxicity, especially with large doses.
Retre-Gel is a trusted 20% benzocaine topical anesthetic gel that dental professionals have relied on for decades. Its rapid onset (30–60 seconds), effective numbing for 15–30 minutes, and excellent tolerability profile make it a practical first-line option for pre-injection mucosal anesthesia, procedure comfort, and short-term oral pain relief. The key things to know: it is not a controlled substance, it is not in a national shortage, and effective OTC equivalents are readily available at retail pharmacies for patients who need immediate access.
The most important safety consideration with Retre-Gel is the FDA's warning about methemoglobinemia risk. This is a rare but serious condition. Always avoid use in children under 2 years of age, disclose nitrate medications and blood disorders to your provider, and seek emergency care immediately if you notice blue or gray skin, lips, or nails after benzocaine use.
If you are having difficulty finding Retre-Gel or any benzocaine topical gel product at a pharmacy near you, medfinder makes the search simple. Enter your medication, dosage, and location — medfinder calls pharmacies near you and texts you the results, saving you time and frustration.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
Real-time availability
Medfinder is actively checking pharmacy inventory for Retre-Gel. We don't publish a number until we have enough verified pharmacy checks to be accurate — start a search and our team confirms current availability near you, usually within 24 hours.
ChatGPT
Claude
Gemini